Paricalcitol in Treating Patients With Myelodysplastic Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00064376|
Recruitment Status : Completed
First Posted : July 9, 2003
Last Update Posted : January 29, 2018
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells.
PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia Myelodysplastic Syndromes||Drug: paricalcitol||Phase 2|
- Determine the clinical effects of paricalcitol in patients with myelodysplastic syndromes.
- Determine whether this drug can improve RBC, WBC, or platelet counts in these patients.
- Determine whether this drug can decrease the risk of development of leukemia without causing undue toxicity in these patients.
OUTLINE: Patients receive oral paricalcitol daily for 4 months in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 8 months.
|Study Type :||Interventional (Clinical Trial)|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes|
|Actual Study Start Date :||May 2003|
|Primary Completion Date :||November 2005|
|Study Completion Date :||November 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00064376
|United States, California|
|Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center|
|Los Angeles, California, United States, 90048|
|Study Chair:||H. Phillip Koeffler, MD||Cedars-Sinai Medical Center|